Global Crigler-Najjar Syndrome Treatment Market, By Type (Crigler-Najjar Syndrome type I, Crigler-Najjar Syndrome Type II), Treatment (Medication, Surgery), Route of Administration (Oral, Injectable), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others),Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Crigler-Najjar Syndrome Treatment Market
The Crigler-Najjar syndrome treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 5.60% in the above-mentioned research forecast period. Huge financial support to the researchers for developing novel intervention is boosting the Crigler-Najjar syndrome treatment market growth.
For instance,
- The gene therapy, AT342 which is given through intravenous route for the treatment of Crigler-Najjar syndrome has completed clinical trial phase I and is under phase II. This gene therapy is tested in the subjects for their efficacy and safety.
- Similarly GNT0003 is a genetic therapy which is used for the treatment of severe Crigler-Najjar syndrome which is under clinical trial.
Crigler–Najjar syndrome is rare genetic liver disorder characterized by abnormal accumulation of bilirubin, a yellow pigment produced by the liver. This accumulation is caused by deficiency of the enzyme called UGT1A1. This enzyme is responsible for the conversion of bilirubin into a substance that can be eliminated. Crigler–Najjar syndrome can cause significant neurological damage. The symptoms for the Crigler–Najjar syndrome type I appear after the birth such as yellow skin and white eye (jaundice kind of symptoms). Other symptoms are absence of reflexes, muscle pain and spasm, vomiting, fever and many other symptoms. The affected population of the syndrome is approximately 1 in 750,000-1,000,000 people and is common in both male and females.
Increase in demand of disease specific novel treatment and family history of Crigler–Najjar syndrome can act as a Crigler-Najjar syndrome treatment market driver. In addition, increase in special designation from the regulatory authorities also act as driver for the Crigler-Najjar syndrome treatment market growth. Lack of healthcare budget in some middle-income countries is restraining the Crigler-Najjar syndrome treatment market growth.
This Crigler-Najjar syndrome treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the Crigler-Najjar syndrome treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Crigler-Najjar Syndrome Treatment Market Scope and Market Size
The Crigler-Najjar syndrome treatment market is segmented on the basis of type, treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the Crigler-Najjar syndrome treatment market is segmented into Crigler-Najjar syndrome type I and Crigler-Najjar syndrome type II.
- On the basis of treatment, the Crigler-Najjar syndrome treatment market is segmented into medication and surgery. Medication is further segmented to bilirubin chelators, ursodeoxycholic acid and others. Surgery is further segmented to liver transplantation.
- On the basis of route of administration, the Crigler-Najjar syndrome treatment market is segmented into oral and injectable.
- On the basis of end-users, the Crigler-Najjar syndrome treatment market is segmented to hospitals, homecare, specialty clinics and others
- On the basis of distribution channel, the Crigler-Najjar syndrome treatment market is segmented into hospital pharmacies, retail pharmacies and others.
Global Crigler-Najjar Syndrome Treatment Market Country Level Analysis
Global Crigler-Najjar syndrome treatment market is analysed and market size information is provided by country, type, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Crigler-Najjar syndrome treatment market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share because of increase in healthcare expenditure and increase in the Crigler-Najjar syndrome treatment market players. Asia-Pacific also holds the Crigler-Najjar syndrome treatment market share due to increase in government initiatives regarding the healthcare development.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The Crigler-Najjar syndrome treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to Crigler-Najjar syndrome treatment market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the Crigler-Najjar syndrome treatment market in the growth period.
Competitive Landscape and Crigler-Najjar Syndrome Treatment Market Share Analysis
The Crigler-Najjar syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Crigler-Najjar syndrome treatment market.
The major players covered in the global Crigler-Najjar syndrome treatment market report are International Stem Cell Corporation, Promethera, Selecta Biosciences, Inc, LOGICBIO THERAPEUTICS, INC, Genethon, Audentes Therapeutics, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Endo Pharmaceuticals Inc, ANI Pharmaceuticals, Inc, Mylan N.V., Glenmark Pharmaceuticals Ltd, Amneal Pharmaceuticals LLC, Epic Pharma, LLC, Lannett among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-